SHORT MINI-FUTURE - GENMAB | Market Closed - Deutsche Boerse AG 19:02:29 14/06/2024 BST | ||
| 21.51 EUR | +0.28% |
|
| Current month | +7.44% | ||
| 1 month | +13.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 21.51 | +0.28% |
| 13/06/24 | 21.45 | +0.61% |
| 12/06/24 | 21.32 | +3.14% |
| 11/06/24 | 20.67 | +2.43% |
| 10/06/24 | 20.18 | +0.55% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 07:02 pm
More quotesStatic data
| Product type | Warrant Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VQ8NBX |
| ISIN | DE000VQ8NBX0 |
| Date issued | 15/06/2021 |
| Strike | 3,440 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 13.74 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.46 € |
|---|---|
| Lowest since issue | 1.76 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,832
DKK
Average target price
2,464
DKK
Spread / Average Target
+34.46%
- Stock Market
- Certificates
- Certificat